Comments
Drug firm Strides Pharma Science on Wednesday reported a consolidated net loss of ₹8.70 crore for the quarter ended September 30, 2018. The company had posted a net profit of Rs 11.73 crore for the corresponding period of the previous fiscal, Strides Pharma Science said in a filing to BSE.
Consolidated revenue from operations stood at ₹732.63 crore for the quarter under consideration. It was ₹768.66 crore for the same period a year ago.
Commenting on the results, Strides Pharma Science Founder and Group CEO Arun Kumar said, “We have achieved significant progress on our reset strategy both in terms of course-correction and execution over the last two quarters.”
With all growth pivots in place, the company is confident of scaling up its diversified B2C business and continue the growth momentum across key markets, he added.
Shares of Strides Pharma Science were trading at Rs 423.10 on the NSE, up 2.36 per cent from their previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.